Search

everythinglearnresearchcommunity

for

Search:↓

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

A user is treating hair loss with Dutasteride, Minoxidil, RU58841, Derminator 2, Vitamin D, Biotin, and Zinc. After 6 months, there's no significant visual improvement, but the user feels less insecure about Retrograde Alopecia.

A 30-year-old male with thinning hair and an itchy, oily scalp found that hydrocortisone cream eliminated dandruff and itching and seemed to thicken his hair. He avoided minoxidil and finasteride due to potential side effects and noted that Nizoral and Head & Shoulders worsened his symptoms.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

Hair loss can be influenced by chronic low-level allergies, and treatments like fexofenadine or topical cetirizine may help with regrowth. The user avoids finasteride, dutasteride, and minoxidil, and has tried Regenera Activa and PRF sessions.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

The user shared progress on hair regrowth using a topical minoxidil/finasteride spray, dermarolling weekly, and a product similar to pp405. They reported some regrowth with no side effects from the new product.

The conversation is about a female's difficulty in obtaining a prescription for a DHT blocker other than Spironolactone for hair loss. She is seeking advice on the severity of her condition and discussing specific treatments like Minoxidil, Finasteride, and RU58841.

The conversation discusses hair loss treatments, focusing on reducing scalp itching and dandruff using natural shampoos, witch hazel, and apple cider vinegar. The user also mentions using finasteride and observing potential regrowth, though it's difficult to confirm.

A 25-year-old male with DUPA (diffuse thinning including the donor area) has not seen improvement after 14 months on finasteride. He's considering switching to dutasteride (DUT) after advice from a hair loss YouTuber and is also contemplating trying RU58841.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

A 24-year-old male started using finasteride, minoxidil, biotin, and vitamin D for hair loss but noticed worsening thinning and white patches on his temples. He seeks advice on improving his regimen, which includes topical minoxidil and a shampoo for seborrheic dermatitis.

Bimatoprost (Latisse) may help with hair thinning but is expensive and less effective than minoxidil or finasteride. Combining treatments like minoxidil, finasteride, and possibly RU58841 could be more effective for hair loss.

The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.

Chronic Telogen Effluvium can be managed by avoiding inflammatory foods, exercising, staying hydrated, and using supplements like krill oil, saw palmetto, or licorice root. Minoxidil is discouraged due to its cost and potential for worsening hair loss, while castor oil is recommended to strengthen hair roots and reduce shedding.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

A user is seeking topical versions of minoxidil and finasteride in Australia that do not contain propylene glycol. They are looking for alternatives due to potential irritation from propylene glycol.

The user experienced severe hair shedding from RU58841 and recovered by stopping its use and starting treatments including Minoxidil, Rosemary Verbenone, Stemoxydine, Aminexil, copper peptide serum, and specific shampoos. They also consistently used oral Finasteride and plan to try Minoxidil 10%.

Fluridil, a non-steroidal anti-androgen approved for alopecia in parts of Europe, is noted for its low side effects but is not commonly discussed. The user is inquiring if anyone prefers it over other anti-androgens like Spiro or RU58841.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

A 17-year-old using 5% topical minoxidil experienced significant hair shedding after a year, possibly due to a "synchronization shed" and deficiencies in vitamin D and iron. Recommendations include continuing minoxidil, optimizing vitamin D and iron levels, and reducing tretinoin use if scalp irritation occurs.

A 28-year-old male is experiencing hair loss, possibly due to seborrheic dermatitis, itchiness, or shampoo use, and is considering treatments other than minoxidil or finasteride. He plans to consult a doctor for further advice.

The user shared progress pictures after three months of using RU58841, finasteride, and OM (oxidative stress modulators) for hair loss treatment. They haven't noticed much change but are seeking feedback on their results.

A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.

Hair thinning/loss associated with burning scalp pain. Finasteride helped relieve "DHT itch" for one person.

The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.

LLLT (low-level laser therapy) is as effective or better than traditional minoxidil treatment for hair growth, with fewer side effects and improved long-term compliance due to milder adverse effects. Studies show LLLT increases hair density more than minoxidil, but drawbacks include the initial cost and the need for long-term use to see results.

The user started using minoxidil foam daily after two years on finasteride and is managing seborrheic dermatitis with antifungal shampoo. They seek advice on moisturizing products that won't worsen their condition, with suggestions including gentle shampoos and light ceramide serums.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.